top of page
Lindsey Folio
Admin
More actions
Profile
Join date: Dec 30, 2019
Posts (15)
May 28, 2026 ∙ 4 min
Breakthrough Device Designation: What It Gets You and What It Doesn't
BDD accelerates FDA engagement and collaboration — it does not lower the evidentiary bar. Here's how to build a regulatory strategy around what it actually does.
0
0
May 24, 2026 ∙ 4 min
Using AI to Draft FDA Submission Content: The Risks That Will Catch You at Review
AI-generated regulatory documentation looks polished but introduces specific failure modes FDA reviewers will identify.
87
0
May 17, 2026 ∙ 6 min
FDA Deficiency Letters: How to Respond Strategically and Keep Your Review Moving Forward
An FDA deficiency letter isn't a rejection, but a disorganized non-targeted response can function like one. Here's a strategic framework for responding without stalling your review.
10
0
bottom of page